Cargando…

Emerging treatment options for nasopharyngeal carcinoma

Nasopharyngeal carcinoma is endemic in Asia and is etiologically associated with Epstein–Barr virus. Radiotherapy is the primary treatment modality. The role of systemic therapy has become more prominent. Based on multiple phase III studies and meta-analyses, concurrent cisplatin-based chemoradiothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lu, Chen, Qiu-Yan, Liu, Huai, Tang, Lin-Quan, Mai, Hai-Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565571/ https://www.ncbi.nlm.nih.gov/pubmed/23403548 http://dx.doi.org/10.2147/DDDT.S30753

Ejemplares similares

Current and emerging treatment options for nasopharyngeal carcinoma
por: Spratt, Daniel E, et al.
Publicado: (2012)

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options
por: Jiromaru, Rina, et al.
Publicado: (2022)

The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy
por: Guo, Shan-Shan, et al.
Publicado: (2014)

LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome
por: Hua, Yi-Jun, et al.
Publicado: (2016)

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
por: Huang, Pei-Yu, et al.
Publicado: (2016)

Alpha-fetoprotein–producing recurrent nasopharyngeal carcinoma: A case report
por: Yang, Zhen-Chong, et al.
Publicado: (2021)

Optimizing the Treatment Pattern for De Novo Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study
por: Sun, Xue-Song, et al.
Publicado: (2020)

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study
por: Sun, Xue‐Song, et al.
Publicado: (2020)

The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways
por: Luo, Dong-Hua, et al.
Publicado: (2013)

Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance
por: Sun, Xue-Song, et al.
Publicado: (2019)

Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options
por: Liu, Zheran, et al.
Publicado: (2021)

The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients
por: Liu, Li-Ting, et al.
Publicado: (2018)

Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study
por: Sun, Xue-Song, et al.
Publicado: (2019)

Stratification of Candidates for Induction Chemotherapy in Stage III-IV Nasopharyngeal Carcinoma: A Large Cohort Study Based on a Comprehensive Prognostic Model
por: Sun, Xue-Song, et al.
Publicado: (2020)

Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II–IVb Nasopharyngeal Carcinoma
por: Li, Ji-Bin, et al.
Publicado: (2020)

Current Treatment Options for Local Residual Nasopharyngeal Carcinoma
por: Stoker, S. D., et al.
Publicado: (2013)

Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis
por: Liu, Huai, et al.
Publicado: (2013)

Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma
por: Chen, Wen-Hui, et al.
Publicado: (2014)

Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma
por: Zhu, Qian‐Ying, et al.
Publicado: (2021)

Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II‐IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort
por: Sun, Xue‐Song, et al.
Publicado: (2020)

Current treatment options for recurrent nasopharyngeal cancer
por: Suárez, Carlos, et al.
Publicado: (2010)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Prognostic effect of pregnancy on young female patients with nasopharyngeal carcinoma: results from a matched cohort analysis
por: Zhang, Lu, et al.
Publicado: (2016)

Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal Carcinoma
por: Guo, Shan-Shan, et al.
Publicado: (2021)

Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
por: Liu, Huai, et al.
Publicado: (2013)

Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
por: Liu, Li-Ting, et al.
Publicado: (2019)

Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
por: Liang, Yu-Jing, et al.
Publicado: (2022)

Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
por: Zhang, Chunye, et al.
Publicado: (2021)

Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma
por: Guo, Shan-Shan, et al.
Publicado: (2022)

Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy
por: He, Jia, et al.
Publicado: (2012)

With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case–control study
por: Liu, Li-Ting, et al.
Publicado: (2016)

Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
por: Liu, Li-Ting, et al.
Publicado: (2020)

Plasma Epstein–Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area
por: Shen, Ting, et al.
Publicado: (2015)

Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Chen, Wen-Hui, et al.
Publicado: (2016)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein–Barr virus DNA level after induction chemotherapy
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection
por: Liu, Sai-Lan, et al.
Publicado: (2022)

Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy
por: Yang, Jin-Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4aebsn3feimv61nfnl473nfuob